Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

Xingrui HeKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaView further author information

Xiabin ChenKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaView further author information

Hancheng ZhangDrug Discovery, Hangzhou Innogate Pharma Co., Ltd, Hangzhou, Zhejiang Province, ChinaView further author information

Tian XieKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaCorrespondence[email protected] [email protected]

http://orcid.org/0000-0001-7066-1443 View further author information

Xiang-Yang YeKey Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang Province, China;Holistic Integrative Pharmacy Institutes (HIPI), School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, ChinaCorrespondence[email protected] [email protected]

http://orcid.org/0000-0003-3739-0930 View further author information

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date